aTyr Pharma, Inc. (ATYR) Key Metrics
ATYR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $17.1M
- Enterprise value
- −$9.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 89.8 10-yr median 214.1
- Price / book
- 0.8 10-yr median 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.91
ATYR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsATYR valuation Price multiples at each fiscal year-end price.
Price / sales
383.2
2025 · hover or tap a bar for each year
20162025
Price / book−71.9%
1.1
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−59.5 pts
−85.2%
2025 · hover or tap a bar for each year
20162025
ATYR returns How much profit the business earns on the capital it uses.
Return on equity−28.1 pts
−107.8%
2025 · hover or tap a bar for each year
20162025
Return on assets−18.7 pts
−77.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover−7.9%
0.00
2025 · hover or tap a bar for each year
20162025
ATYR per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−35.4%
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.80
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.67
2025 · hover or tap a bar for each year
20162025
Book value per share−23.0%
$0.73
2025 · hover or tap a bar for each year
20162025
Shares outstanding+25.2%
93.0M
2025 · hover or tap a bar for each year
20162025
ATYR financial health Debt, liquidity and how easily interest is covered.
Debt / equity−6.0%
0.18
2025 · hover or tap a bar for each year
20162025
Net debt−$7.8M
−$66.7M
2025 · hover or tap a bar for each year
20162025
Current ratio−3.3%
5.30
2025 · hover or tap a bar for each year
20162025
Debt / assets−6.8%
0.13
2025 · hover or tap a bar for each year
20162025
ATYR efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−734 days
2,506 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+35 days
965 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−769 days
1,541 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+12.9 pts
40.5%
2025 · hover or tap a bar for each year
20162025
ATYR valuation history
Fiscal year-endToday10-year median
ATYR returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ATYR debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ATYR price vs earnings per share
Share price at year-endEPS (right axis)
ATYR key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $72.8M | $268.8M | $75.6M | $62.2M | — | — | — | — | — | — |
| Enterprise value | $6.2M | $210.0M | −$7.5M | $7.6M | — | — | — | — | — | — |
| Price / sales | 383.2 | — | 214.1 | 6.0 | — | — | — | — | — | — |
| Price / book | 1.1 | 3.8 | 0.8 | 0.9 | — | — | — | — | — | — |
| EV / sales | 32.4 | 893.5 | -21.2 | 0.7 | — | — | — | — | — | — |
| Earnings yield | −101.8% | −23.8% | −66.7% | −72.8% | — | — | — | — | — | — |
| Free cash flow yield | −85.2% | −25.7% | −49.5% | −69.9% | — | — | — | — | — | — |
| Share price at fiscal year-end | $0.78 | $3.62 | $1.41 | $2.19 | $7.47 | $3.88 | $4.17 | $6.94 | $49.00 | $30.10 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.01 | $0.37 | — | — | — | — | — | — |
| Earnings per share | −$0.80 | −$0.86 | −$0.94 | −$1.60 | — | — | — | — | — | — |
| Operating cash flow per share | −$0.67 | −$0.93 | −$0.62 | −$1.47 | — | — | — | — | — | — |
| Free cash flow per share | −$0.67 | −$0.93 | −$0.70 | −$1.53 | — | — | — | — | — | — |
| Cash per share | $0.85 | $0.97 | $1.83 | $2.33 | — | — | — | — | — | — |
| Book value per share | $0.73 | $0.94 | $1.69 | $2.51 | — | — | — | — | — | — |
| Tangible book value per share | $0.73 | $0.94 | $1.69 | $2.51 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.08 | $0.06 | — | — | — | — | — | — |
| Debt per share | $0.13 | $0.18 | $0.28 | $0.41 | — | — | — | — | — | — |
| Shares outstanding | 93.0M | 74.3M | 53.6M | 28.4M | — | — | — | — | — | — |
| Change in shares outstanding | +25.2% | +38.5% | +88.6% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −107.8% | −79.7% | −62.2% | −50.2% | −47.9% | −61.4% | −86.1% | −70.5% | −75.9% | −65.1% |
| Return on invested capital (ROIC) | — | −571.9% | −355.1% | −373.7% | — | −632.8% | — | — | — | −377.3% |
| Return on assets (ROA) | −77.6% | −58.9% | −46.6% | −42.9% | −43.8% | −43.3% | −53.1% | −48.6% | −56.8% | −55.0% |
| Return on tangible assets | −78.7% | −66.1% | −41.8% | −47.3% | −29.2% | −41.9% | −65.2% | −65.4% | −53.9% | −71.8% |
| Free cash flow margin | — | — | — | −419.1% | — | −148.3% | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $12.0M | $13.3M | $15.1M | $11.5M | $1.4M | $2.2M | $11.7M | $16.0M | $19.7M | $9.5M |
| Cash & short-term investments | $78.7M | $72.1M | $98.2M | $66.1M | $107.9M | $31.7M | $31.1M | $49.5M | $85.1M | $72.1M |
| Net debt | −$66.7M | −$58.8M | −$83.1M | −$54.6M | −$106.5M | −$29.4M | −$19.4M | −$33.5M | −$65.4M | −$62.6M |
| Debt / equity | 0.18 | 0.19 | 0.17 | 0.16 | 0.01 | 0.07 | 0.55 | 0.48 | 0.31 | 0.15 |
| Debt / assets | 0.13 | 0.14 | 0.13 | 0.12 | 0.01 | 0.06 | 0.32 | 0.30 | 0.22 | 0.12 |
| Current ratio | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 | 6.06 | 2.47 | 4.69 | 8.37 | 8.77 |
| Quick ratio | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 | 6.06 | 2.47 | 4.69 | 8.37 | 8.77 |
| Working capital | $65.1M | $67.0M | $86.6M | $67.0M | $107.6M | $29.7M | $19.0M | $40.0M | $76.6M | $66.2M |
| Invested capital | $826,000 | $11.2M | $7.6M | $16.9M | $2.8M | $2.2M | $1.8M | $135,000 | −$1.1M | $191,000 |
| Tangible asset value | $67.3M | $69.8M | $90.5M | $71.3M | $109.1M | $31.5M | $21.0M | $33.6M | $64.2M | $62.8M |
| Net current asset value | $53.4M | $55.0M | $72.8M | $56.4M | $107.2M | $28.3M | $16.8M | $31.7M | $61.9M | $57.0M |
| Graham net-net per share | $0.56 | $0.63 | $1.30 | $1.78 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | 40.5% | 27.7% | 1,194.1% | 15.8% | — | 1.9% | 18.7% | — | — | — |
| Capex / depreciation | 0.05 | 0.04 | 1.54 | 0.97 | 0.15 | 0.16 | 0.06 | 0.80 | 1.84 | 0.67 |
| Stock-based compensation / revenue | 2,630.0% | 1,271.9% | 736.5% | 20.7% | — | 14.0% | 422.5% | — | — | — |
| R&D / revenue | 31,694.2% | 23,137.0% | 11,981.0% | 412.2% | — | 165.4% | 3,328.9% | — | — | — |
| SG&A / revenue | 9,262.1% | 5,862.6% | 3,676.8% | 134.6% | — | 86.8% | 2,216.1% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 2,506.0 | 3,240.0 | 7,347.0 | 214.6 | — | 37.3 | 86.5 | — | — | — |
| Days payables outstanding | 965.3 | 930.5 | 441.8 | 445.4 | 344.6 | 24.0 | 24.5 | 811.2 | 1,249.6 | 1,313.6 |
| Cash conversion cycle (days) | 1,540.7 | 2,309.4 | 6,905.3 | -230.9 | — | 13.3 | 62.0 | — | — | — |
| Receivables turnover | 0.15 | 0.11 | 0.05 | 1.70 | 0.00 | 9.78 | 4.22 | — | — | — |
| Payables turnover | 0.38 | 0.39 | 0.83 | 0.82 | 1.06 | 15.18 | 14.89 | 0.45 | 0.29 | 0.28 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.28 | 0.01 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.3M | $2.1M | $7.1M | $6.1M | $1.2M | $1.1M | $100,000 | — | — | — |
| Average payables | $4.1M | $3.9M | $3.3M | $2.1M | $1.2M | $1.1M | $943,500 | $1.7M | $2.4M | $3.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ATYR's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ATYR valuation and financial ratios
aTyr Pharma earned a return on equity of −107.8% in fiscal 2025. It ended the year with $12.0 million of debt and $78.7 million in cash and short-term investments, a net cash position of $66.7 million.
See the ATYR income statement, the ATYR chart for price history, or the ATYR stock overview for the latest quote and news.
ATYR key metrics FAQ
What is aTyr Pharma's return on equity?
aTyr Pharma's return on equity (ROE) was −107.8% in fiscal 2025: net income of -$74.1 million on average shareholders' equity of $68.7 million.
How much debt does aTyr Pharma have?
aTyr Pharma had total debt of $12.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
What is aTyr Pharma's free cash flow yield?
aTyr Pharma generated -$62.1 million of free cash flow in fiscal 2025, a free cash flow yield of −85.2% on its market value at year-end ($72.8 million).
What is aTyr Pharma's current ratio?
aTyr Pharma's current ratio was 5.30 at the end of fiscal 2025: current assets were 5.30 times current liabilities.